Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF
Letter to the Editor - Study Letter
2017:83:2;249-251
doi: 10.4103/0378-6323.193617
PMID: 27852993

In vitro antifungal susceptibility of Malassezia isolates from pityriasis versicolor lesions

Ajanta Sharma1 , Debajit Rabha1 , Giasuddin Ahmed2
1 Department of Microbiology, Gauhati Medical College, Gauhati, Assam, India
2 Department of Biotechnology, Gauhati University, Guwahati, Assam, India

Correspondence Address:
Ajanta Sharma
Department of Microbiology, Gauhati Medical College, Gauhati - 781 032, Assam
India
How to cite this article:
Sharma A, Rabha D, Ahmed G. In vitro antifungal susceptibility of Malassezia isolates from pityriasis versicolor lesions. Indian J Dermatol Venereol Leprol 2017;83:249-251
Copyright: (C)2017 Indian Journal of Dermatology, Venereology, and Leprology

Sir,

Pityriasis versicolor is the only human disease for which Malassezia has been fully established as a pathogen. The genus Malassezia includes 15 lipophilic species with the recent addition of one new species Malassezia arunalokei”. Traditionally, Malassezia furfur, Malassezia sympodialis, Malassezia globosa and Malassezia restricta have been considered the major pathogenic species implicated in dermatological disorders.[1],[2] Since Malassezia species are a part of the normal flora of skin, it is impossible to eradicate them permanently by topical and systemic antifungals resulting in relapses in predisposed individuals. Antifungal susceptibility testing is warranted for Malassezia yeasts, as they are implicated in both cutaneous and invasive infections in humans.

Because of the lipophilic nature, antifungal susceptibility testing of Malassezia yeasts is still a problem and hence, little work has been published on the in vitro susceptibilities of Malassezia to various antifungal agents. Various workers have evaluated the antifungal susceptibility of Malassezia employing modified Clinical Laboratory Standard Institute (CLSI) broth microdilution technique, using different culture media. These studies have reported significant variations in minimum inhibitory concentrations resulting in erroneous susceptibility classification. Hence, the present study aimed at the evaluation of in vitro susceptibility of Malassezia species to amphotericin B, ketoconazole, fluconazole, itraconazole and voriconazole by Clinical Laboratory Standard Institute (CLSI) protocol M27-A3 using modified Christensen's urea broth.[3],[4]

During the period 2012-2015, in the Department of Microbiology, Gauhati Medical college, Assam, Malassezia species were isolated from 290 patients with pityriasis versicolor and identified as M furfur (241), M. globosa (27), M. restricta (8), M. obtusa (7), M. sympodialis (5), M. slooffiae (1) and M. japonica (1) by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) of 26SrDNA region followed by sequencing.[5] Reference strains of Malassezia (M. furfur Microbial Type Culture Collection, Institute of Microbial Technology, Chandigarh, India, MTCC1374, M. globosa Centraalbureau Schimmelcultures-KNAW Fungal Biodiversity Centre, Utrecht, the Netherlands CBS7886, M. restricta CBS7877, M. japonica CBS9432, M. slooffiae CBS7956 and M. pachydermatis MTCC1369) and quality control strains C. albicans ATCC (American Type Culture Collection) 90028 and C. krusei (American Type Culture Collection) 6258 were tested as controls.

The concentration of the yeast suspensions (106 cfu/ml) were adjusted by spectrophotometer.[4] Stock suspensions of amphotericin B, ketoconazole, fluconazole, itraconazole and voriconazole (Sigma-Aldrich, USA), were prepared in dimethyl sulfoxide. The different drug concentrations varied between 0.125-64 μg/ml for fluconazole and between 0.0313-16 μg/ml for all other antifungals. Antifungal susceptibility testing was performed in 96-well microtiter plates and cultures were incubated at 32°C ± 2°C for 96 hours for M. globosa and M. restricta and 72 hours for other species.[3],[4] The final mean optical density obtained for each antifungal concentration was expressed as percentage of growth control. For azoles, the minimum inhibitory concentration endpoints of the antifungals were defined as the lowest drug concentrations that showed an optical density of ≤50% of that of the (drug-free) growth control. For amphotericin B, minimum inhibitory concentration endpoint was defined as the lowest concentration that completely inhibited growth.[4]

[Table - 1] summarizes the minimum inhibitory concentration (range, geometric mean & mode) and minimum inhibitory concentrations where 50% and 90% of the isolates were inhibited (MIC50 and MIC90) obtained for the antifungal drugs. The minimum inhibitory concentration of ketoconazole, itraconazole and voriconazole was 1 μg/ml for 90% of the M. furfur and M. globosa isolates; however, the minimum inhibitory concentration of amphotericin B for M. furfur was higher than that for M. globosa (1 μg/ml versus 0.5 μg/ml). Fluconazole minimum inhibitory concentrations were higher than other azoles and ranged from ≤0.12 to >64 μg/ml for M. furfur, ≤0.12 to 8 μg/ml for M. globosa and M. restricta. M. globosa showed higher minimum inhibitory concentration ranges to all the azoles. The geometric mean and mode for all drugs tested were higher for M. furfur, M. globosa and M. restricta especially for fluconazole, itraconazole and voriconazole.

Table 1: Minimum inhibitory concentration (MIC) ranges, geometric mean, mode, MIC50, and MIC90 obtained by broth microdilution method for 290 Malassezia isolates

In this study, the Malassezia species could be divided into two groups. M. sympodialis, M. obtusa, M. slooffiae and M. japonica were more susceptible to antifungals while M. furfur, M. globosa and M. restricta comprised the less susceptible group. Every result obtained using this method demonstrated good reproducibility. The overall data shows that, the non-applicability of Clinical Laboratory Standard Institute M27-A3 protocol for Malassezia species has resulted in variations in methodologies for minimum inhibitory concentration determination with limited inter laboratory agreement. The original Clinical Laboratory Standard Institute protocol has been modified by using a more suitable growth medium, increasing the inoculum size to counteract the slower growth of Malassezia, increasing incubation time and altering the definition of the minimum inhibitory concentration end point.

In conclusion, modified Christensen's urea broth may be used for antifungal susceptibility testing of Malassezia with optimum testing conditions such as standardization of inocula, incubation temperature and time.

Acknowledgement

I gratefully acknowledge the Department of Biotechnology (DBT), Ministry of Science and Technology, Government of India, for their financial support in this work under Research & Development project grant vide sanction number BT/PR3633/MED/29/330/2011 dated 26/03/2011. I also express my sincere gratitude to Dr. Arunaloke Chakrabarti, Professor and Head, Dr. M.R. Shivaprakash, Additional Professor, Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh for providing some of the reference strains.

Financial support and sponsorship

Department of Biotechnology (DBT), Ministry of Science and Technology, Govt. of India, New Delhi.

Conflicts of interest

There are no conflicts of interest.

References
1.
Gaitanis G, Magiatis P, Hantschke M, Bassukas ID, Velegraki A. The Malassezia genus in skin and systemic diseases. Clin Microbiol Rev 2012;25:106–41.
[Google Scholar]
2.
Honnavar P, Prasad GS, Ghosh A, Dogra S, Handa S, Rudramurthy SM. Malassezia arunalokei sp. nov., a novel yeast species isolated from seborrhoeic dermatitis patients and healthy individuals from India. J Clin Microbiol 2016;54:1826-34.
[Google Scholar]
3.
CLSI. Reference Method for Broth dilution antifungal susceptibility testing of yeasts; approved standard, CLSI document M27-A3. -3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
[Google Scholar]
4.
Rincón M, Cepero de García C, Espinel-Ingroff A. A Modified Christensen's Urea and CLSI Broth Microdilution Method for Testing Susceptibilities of Six Malassezia Species to Voriconazole, Itraconazole, and Ketoconazole. J Clin Microbiol 2006;44:3429-31.
[Google Scholar]
5.
Mirhendi H, Makimura K, Zomorodian K, Yamada T, Sugita T, Yamaguchi H. A simple PCR-RFLP method for identification and differentiation of 11 Malassezia species. J Microbiol Methods2005;61:281-4.
[Google Scholar]

Fulltext Views
66

PDF downloads
31
Show Sections